Biome Australia Ltd · ASX:BIO
Biome Australia — Investor Presentation (September 2024)
27 slides from Biome Australia's investor presentation, Sep 30, 2024
Slide 1: Vision 27 Strategic Plan
Biome Australia Group The Microbiome Health Company September 2024 Vision 27 Jan 2024 Strategy Meeting Strategic Plan Blair Norfolk, CEO & Managing Director Vision 27 Strategic Plan 1
Slide 2: Disclaimer
Biome Australia Group The Microbiome Health Company Disclaimer This presentation and the information contained within it (the This presentation contains forward-looking statements, which may be The recipient must, and agrees with the Company that it will, make its “information”) has been prepared so
Slide 3: About Biome Australia
Biome Australia Group The Microbiome Health Company About Biome Australia Biome Australia (ASX: BIO) is focused on becoming a global leader in the complementary medicine industry, offering clinically-proven, condition-specific probiotic products fueled by novel clinical research programs to cement and
Slide 4: Our mission
Biome Australia Group The Microbiome Health Company Our mission To prevent disease, improve health outcomes and quality of life, and make our products accessible to all Vision 27 Strategic Plan 4
Slide 5: Biome Australia Group The Microbiome Health Company Vision 27 Strategic Plan
Biome Australia Group The Microbiome Health Company Vision 27 Strategic Plan 5
Slide 6: Biome Underlying Business
Biome Australia Group The Microbiome Health Company Biome Underlying ● Biome became both cash flow and EBITDA positive in the second half of FY24 Business ● International market expansions are well underway after successful test market was Growth & Development completed in the UK and Ireland, Biome r
Slide 7: Biome Underlying Business
Biome Australia Group The Microbiome Health Company Biome Underlying ● Ongoing clinical research and development pipeline (low cost) which drives Business product development, additional trust and support of health professionals Growth & Development ● Activated Probiotics is the highest growth pract
Slide 8: Vision 27
Biome Australia Group The Microbiome Health Company Vision 27 Vision 27 Strategic Plan 8
Slide 9: Vision 27
Biome Australia Group The Microbiome Health Company Vision 27 Vision 27 ‒ Biome’s strategic plan is to grow from a successful ASX microcap company to a major player in the Australian and global complementary Bring Activated Probiotics to the medicine markets. Biome will look to maintain cash flow pos
Slide 10: Vision 27
Biome Australia Group The Microbiome Health Company Vision 27 2. International Market Acceptance and Growth ● Gain traction and brand recognition as well as meaningful sales volume Bring Activated Probiotics to the in both European and North American markets mainstream market as a significant ○ Furth
Slide 11: Australian Market
Biome Australia Group The Microbiome Health Company Distribution growth & Business Development Pharmacy & Health Food Distribution Channel Australian Market ● Distribution growth ○ Develop the existing 5000 Australian distribution points (Pharmacy and Practitioner) to 8000 by the close of FY27 (67%
Slide 12: International Markets
Biome Australia Group The Microbiome Health Company International Markets In FY24 revenue in international markets grew 95% to reach ~$895k Biome looks for markets outside Australia that have a number of specific traits: ● Strong health and service based pharmacy market Maintain High Growth ● Establi
Slide 13: Biome existing footprint and Vision 27 distribution growth
Biome Australia Group The Microbiome Health Company Biome existing footprint and Vision 27 distribution growth Practitioner & Pharmacy Practitioner only Pharmacy only Vision 27 Strategic Plan 13
Slide 14: International Markets
Biome Australia Group The Microbiome Health Company International Markets Biome has several markets at various stages of development Biome tasks a conservative and considered approach to each market Test markets & markets under review and channel within each market and only invests once a review is
Slide 15: Europe
Biome Australia Group The Microbiome Health Company International Markets Biome Australia Trading UK (Europe) Europe Biome has established a base of operations out of the United Kingdom over the past 3 years to support the company's future growth and development plans throughout Europe. The existing
Slide 16: Europe
Biome Australia Group The Microbiome Health Company International Markets Heath Retail Europe ● ● Community Pharmacy and Health Food stores launched in FY25 Strong growth expected and strategy in place to grow rate of sales in health retail market (UK & Ireland) ○ Significant growth expected through
Slide 17: New Zealand
Biome Australia Group The Microbiome Health Company International Markets Practitioner New Zealand ● ● Strong sales growth - in excess of 100% in FY24 Biome trained Practitioner Education Consultant and Territory manager recruited in FY24, now working to develop local accounts ● Significant growth ex
Slide 18: North America Canada
Biome Australia Group The Microbiome Health Company International Markets Pre Test Market Launch North America ● ● Health Canada Product Registrations and approvals received in H2 FY24 Distribution deal signed with Ecotrend, a leading wholesaler to Canada healthcare practitioners and independent hea
Slide 19: Staffing and Growth Model
Biome Australia Group The Microbiome Health Company International Markets Staffing and Growth Model ● Biome will seek to replicate its Australian success with a lean operational model, heavily weighted towards sales and education human resourcing ● Each territory has existing team members (UK & Irelan
Slide 20: Replicating the Australian success with a fraction of the investment
Biome Australia Group The Microbiome Health Company Replicating the Australian success with a fraction of the investment ● Australia grew from $830K to $12.1M (ex International) between FY20 and FY24 ● Biome plans to leverage its skilled Australian team, to support cost effective international market
Slide 21: Supply Chain
Biome Australia Group The Microbiome Health Company Supply Chain IP Development of Novel Probiotic Strain & Probiotic Production Biome has executed an agreement to develop a Biome owned novel probiotic strain The strain is well under way in development. The current steps for this process are commerc
Slide 22: Supply Chain (Existing)
Biome Australia Group The Microbiome Health Company Supply Chain (Existing) Vision 27 Strategic Plan 22
Slide 23: New brand and product range launch
Biome Australia Group The Microbiome Health Company New brand and Activated X Brand Biome has identified a gap in the market between its existing clinically product range launch proven range of targeted probiotics, Activated Probiotics, and other professional offerings in the complementary medicine ma
Slide 24: Vision 27 Summary
Biome Australia Group The Microbiome Health Company Vision 27 Summary 2. International Market Acceptance and Growth Revenue Growth ● Gain traction and brand recognition as well as meaningful sales volume in both European and North American markets Biome has a three year cumulative sales revenue targ
Slide 25: Risk statement
Biome Australia Group The Microbiome Health Company Risk statement 1. Early stage risk 5. Loss of key management personnel 8. Regulatory risks Whilst the Company became Biome became both cash flow and EBITDA There is substantial competition for personnel in the Company’s industry, and The Company is
Slide 26: Risk statement
Biome Australia Group The Microbiome Health Company Risk statement 12. Changes in strategy 10. Sufficiency of funding The Company’s plans and strategies (including those set out in this There is a risk that the costs of operations may be higher than presentation as the Vision 27 plan) may evolve over
Slide 27: Contact details
Biome Australia Group The Microbiome Health Company Contact details Blair Norfolk, CEO Douglas Loh, CFO Email corporate@biomeaustralia.com Websites biomeaustralia.com activatedprobiotics.com.au Vision 27 Strategic Plan 27
Biome Australia — Investor Presentation (September 2024) on 6ix